Abstract
The aim of the present study is to investigate anticancer effect and mechanism of regorafenib in bladder cancer in vitro and in vivo. Human bladder cancer TSGH 8301 cells were treated with regorafenib, NF-κB, AKT, or mitogen-activated protein kinase (MAPK) inhibitors for different time. The changes of cell viability, NF-κB activation, apoptotic signaling transduction, and expression of tumor progression-associated proteins were evaluated with MTT, NF-κB reporter gene assay, flow cytometry, and Western blotting assay. TSGH 8301 tumor bearing mice were established and treated with vehicle (140 μL of 0.1% DMSO) or regorafenib (10 mg/kg/day by gavage) for 15 days. The changes of tumor volume, body weight, NF-κB activation, MAPK activation, and tumor progression-associated proteins (MMP-9, XIAP, VEGF, and Cyclin-D1) after regorafenib treatment were evaluated with digital caliper, digital weight, and ex vivo Western blotting assay. Our results demonstrated NF-κB activation and protein levels of MMP-9, XIAP, VEGF, and Cyclin-D1 were significantly reduced by NF-κB (QNZ), ERK (PD98059), and P38 (SB203580) inhibitors. Regorafenib also significantly induced extrinsic and intrinsic apoptotic signaling transduction in bladder cancer in vitr...Continue Reading
References
May 1, 1996·Environmental Health Perspectives·C C Harris
May 12, 1997·Mutation Research·M C Poirier, F A Beland
Oct 3, 2002·Journal of Neurochemistry·Susan S WigdalMary Haak-Frendscho
Apr 10, 2004·Urology·Lynsey A McHughJ Kilian Mellon
Aug 11, 2005·British Journal of Cancer·K YamanaY Tomita
Jul 21, 2006·Immunity & Ageing : I & a·Andrea KunzmannAlexander Bürkle
May 15, 2007·Oncogene·A S DhillonW Kolch
Jun 15, 2007·Toxicologic Pathology·Susan Elmore
Jan 14, 2010·Cancer Research·Binod KumarHari K Koul
Jul 13, 2012·Environmental Health : a Global Access Science Source·Silvia LetašiováAlena Bartonová
Apr 5, 2013·Environmental Toxicology·Chin-Chih HoJing-Gung Chung
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Mar 7, 2014·World Journal of Urology·Jianwen WangNianzeng Xing
Apr 24, 2014·Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer·Thomas J Ettrich, Thomas Seufferlein
Jan 1, 2012·Biomolecules·Hui Ling Ko, Ee Chee Ren
Dec 30, 2014·Carcinogenesis·Neelam MukherjeeRita Ghosh
Apr 3, 2015·Cold Spring Harbor Perspectives in Medicine·Richard Sever, Joan S Brugge
Apr 18, 2015·The Urologic Clinics of North America·Emmet J Jordan, Gopa Iyer
Nov 29, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Annalisa MazzottaAnita Mangia
Feb 4, 2016·Scientific Reports·Nien-Cheng ChenFen-Pi Chou
Nov 12, 2016·Journal of Ethnopharmacology·An-Cheng HuangJing-Gung Chung
Nov 30, 2016·Oncology Letters·Ying LiuHui Liu
Dec 6, 2016·International Neurourology Journal·Hong-Tao LiGangning Liang
Dec 10, 2016·Lancet·Jordi BruixUNKNOWN RESORCE Investigators
Dec 22, 2016·Oncology Reports·Jai-Jen TsaiFei-Ting Hsu
Feb 1, 2017·Scientific Reports·Xiaolu CuiXiankui Liu
Feb 15, 2017·Journal of Oncology·Ola A HarbKhaled M Abdel Wahab
Sep 21, 2017·Oncology Letters·Wei-Lung ChenFei-Ting Hsu
Mar 8, 2018·Oncogene·Qi LiuHenning Willers
Mar 15, 2018·Bioscience Reports·Mao-Chi WengHsin-Ell Wang
Mar 30, 2018·Molecular Cancer Therapeutics·Satoshi InoueHiroshi Miyamoto
Nov 23, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Lin YeGuosheng Ren
Citations
Mar 10, 2020·Journal of Cellular and Molecular Medicine·Fei-Ting HsuWei-Shu Wang
Jan 10, 2020·Environmental Toxicology·Yi-Ching ChenChun-Yi Chuang
May 21, 2020·International Journal of Molecular Sciences·Chun-Min SuFei-Ting Hsu
Nov 13, 2020·Frontiers in Pharmacology·Xiao-Long YuanPeng Zhang
Dec 5, 2020·Cancer Management and Research·Dandan QiuZhicheng Cong
Feb 2, 2021·Oxidative Medicine and Cellular Longevity·Chenglin HanXunbo Jin
Jul 28, 2020·Life Sciences·Manav Gandhi, Sujit Nair
Jul 29, 2021·Cancer Cell International·Yongwen LuoTao Liu